1. FFCD. Que faire devant un cancer digestif en 2003? Recommandations de la Fédération Francophone de Cancérologie Digestive (FFCD). 1ère partie. Gastroenterol Clin Biol 2002;26:1140-64. [on line]. 2005. 2. Adenis A, Conroy T, Lasser P, Merrouche Y, Monges G, Rivoire M, et al. Standards, options et recommandations pour la prise en charge des patients atteints de cancer du côlon. In: Fédération Nationale des Centres de Lutte Contre le Cancer, ed. Recommandations pour la pratique clinique en cancérologie [CD-ROM]. 2nd ed. Paris: FNCLCC, John Libbey EUROTEXT, 1998. SOR. 3. Conroy T, Gory-Delabaere G, Adenis A, Bosquet L, Bouché O, Louvet C, et al. Recommandations pour la pratique clinique : Mise à jour 2003 des Standards, Options et Recommandations pour la prise en charge par chimiothérapie palliative de première ligne des patients atteints d’un cancer colorectal métastatique (mise à jour 2003). Gastroenterol Clin Biol 2004;28:E1-E71. 4. GERCOR. Les Recommandations thérapeutiques (côlon) [on line]. 2005 5. Conférence de Consensus. Conclusions et recommandations du jury. Texte de Consensus. Prévention, dépistage et prise en charge des cancers du côlon. Gastroenterol Clin Biol 1998;22 : S275-88. 6. Recommandations pour la pratique clinique : prise en charge thérapeutique des métasatases hépatiques des cancers colorectaux. Gastroenterol Clin Biol 2003;27:B1-B104. 7. Conroy T, Adenis A, Bouche O, Merrouche Y, Mitry E, Gory-Delabaere G. Standards, Options et Recommandations. Bulletin de synthèse de veille 2005 Recommandations pour la pratique clinique : prise en charge par chimiothérapie palliative de première ligne des patients atteints d’un cancer colorectal métastatique. Bull Cancer 2006;93:197-200. 8. Benoist S, Brouquet A, Penna C, Julié C, El Hajjam, Chagnon S, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure ? J Clin Oncol 2006;24:3939-45. 9. Gallix B. Quels sont les examens à réaliser dans le bilan d’extension préthérapeutique ? Critères de qualité et résultats attendus. Gastroenterol Clin Biol 2003;27(suppl2):B25-B40. 10. Chiche L. Quelles métastases hépatiques sont résécables d’emblée ? Gastroenterol Clin Biol 2003;27(suppl2):B41-B62 11. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. Cancer 1996;77:1254-62. 12. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG et ai. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-46. 13. Rivoire M. Peut-on rendre résécables des métastases hépatiques initialement non résécables ? Gastroenterol Clin Biol 2003;27(suppl2):B88-B104. 14. Elias D, Detroz B, Lasser P, Plaub B, Jerbi G. Is simultaneous hepatectomy and intestinal anatomosis safe ? Am J Surg 1995;169:254-60. 15. Elias D, Ouellet JF, de Baere T, Lasser P, Roche A. Preoperative selective portal vein embolization before hepatectomy for liver metastaese : long term results and impact on survival. Surgery 2002;131:294-9. 16. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000;232:777-85. 17. Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology 2004;51:1788-91. 18. Guimbaud R. Quelle est la place de la chimiothérapie néoadjuvante, adjuvante et palliative dans la prise en charge des métastases hépatiques d’origine colorectale ? Gastroenterol Clin Biol. 2003;27(suppl2):B63-79. 19. Parikh AA, Curley SA, Fornage BD, Ellis LM. Radiofrequency ablation of hepatic metastases. Semin Oncol 2002;29:168-82. 20. De Baere T. Modalités et faisabilité des traitements par destruction locale des métastases hépatiques. Gastroenterol Clin Biol 2003;27(suppl2):B80-B87. 21. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284-92. 22. Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004;91:747-54. 23. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-43. 24. Köhne CH, Cunningham D, Di CF, Glimelius B, Blijham G G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002 ;20 :308-17. 25. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study. J Clin Oncol 1997;15:808-15. 26. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer : a multicentre randomised trial. Lancet 2000 ; 355 : 1041-7. 27. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229-37. 28. Mitry E, Tournigand C, André T, Douillard JY, Louvet C, Cunningham D, et al. Comparison of the tolerance and efficacy of LV5FU2-CPT11 and FOLFIRI regimens in front-line treatment of advanced colorectal cancer – A pooled analysis of 254 patients included in 2 randomised trials (abstract). Proc Am Soc Clin Oncol 2004;23:3576a. 29. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and 5-fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 2000; 18: 2938-47. 30. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30. 31. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht R, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005 ;23 :3697-705. 32. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5. 33. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004 ;350:2335-42. 34. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M,et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol 2006;24:394-400. 35. Maughan TS, James RD, Kerr DJ, Ledermann JA, Seymour M, Topham C, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer : a multicenter randomised trial. survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2003;361:457-64. 36. Tournigand C, de Gramont A, Louvet C, André T, Carola E, Gilles Amar V, et al. A simplified bimonthly regiment with leucovorin (LV) and 5-fluorouracil (5FU) for metastatic colorectal cancer (MCRC) (abstract). Proc Am Soc Clin Oncol 1998;17:274a. 37. Ducreux M, Bouche O, Pignon JP, Mousseau M, Raoul JL, Cassan P et al. Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer. Final Results of the Federation Francophone de Cancerologie Digestive (FFCD) 9601 Trial. Oncology 2006;70:222-30. 38. van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M et al. - Oral Capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106. 39. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer : results of a randomized phase III study. J Clin Oncol 2001;19:2282-92. 40. Douillard JY, Hoff PM, Skillings JR, Eisenberg P, Davidson N, Harper P, et al. Multicenter phase III study of uracil/ tegafur UFT and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-16. 41. Carmichael J, Popiela T, Radstone S, Falk S, Borner M, Oza A, et al. Randomized comparative study of tegafur/uracil plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. J Clin Oncol 2002;20:3617-27. 42. Elias D, Di Pietroantonio, Gachot B, Menegon P, Hakime A, de Baere T. Liver abscess after radiofrequency ablation of tumors in patients with a biliary tract procedure. Gastroenterol Clin Biol 2006;30:823-7. 43. Portier G, Elias D, Bouche O, Rougier P, Gillet M, Bosset JF et al. Multicenter randomized trial of adjuvant systemic chemotherapy using 5-Fluorouracil and folinic acid versus observation after resection of liver metastases of colorectal origin. Results of an intergroup phase III study (FFCD-ACHBTH-AURC 9002 trial). J Clin Oncol 2006 ;24 :4976-82. 44. Mitry E, Fields A, Bleiberg H, Labianca R, Portier G, Tu D et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials (abstract). J Clin Oncol 2006;24 (Suppl 18S):3524a. 45. Meta-Analysis Group in Cancer. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996;88:252-8. 46. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma : long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-8. 47. Kerr DJ, McArdle CS, Ledermann J, Taylor I, Sherlock DJ, Schlag PM, et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases : a multicentre randomised trial. Lancet 2003 ; 361 : 368-73. 48. Gamelin E, Danquechin-Dorval EM, Dumesnil YF, Maillart PJ, Goudier MJ, Burtin PC, et al. Relationship between 5-fluorouracil (5FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5FU. Cancer 1996;77:441-51. 49. Gamelin E, Boisdron-Celle M, Delva R, Rebimbeau C, Cailleux PE, Alleaume C, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin : results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998;16:1470-8. 50. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, et al. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Tomudex colorectal cancer study group. Ann Oncol 1996;7:961-5. 51. Cocconi G, Cunningham D, Van Cutsem E, François E, Gustavsson B, van Hazel G, et al. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex colorectal cancer study group. J Clin Oncol 1998;16:2943-52. 52. Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour M, et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555-63. 53. Seitz JF, Bennouna J, Paillot B, Gamelin E, Francois E, Conroy T et al. Multicenter non-randomized phase II study of raltitrexed and oxaliplatin in non pre-treated metastatic colorectal cancer patients. Ann Oncol 2002;13:1072-9. 54. Scheithauer W, Kornek GV, Schuell B, Ulrich-Pur H, Penz M, Raderer M et al. Second line treatment with oxaliplatin plus raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Ann Oncol 2001;12:709-14. 55. Scheithauer W, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Gedlicka C, et al. Randomized multicenter phase II trial of oxaliplatin plus irinotecan versus raltitrexed as first-line treatment in advanced colorectal cancer. J Clin Oncol 2002;20:165-72. 56. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-14. 57. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 1998;16:2739-44. 58. Ducreux M, Ychou M, Seitz J-F, Bonnay M, Bexon A, Armand J-P, et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen) : a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999;17:2901-8. 59. André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 1999;35;9 :1343-7. 60. André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999;17;11:3560-8. 61. Maindrault-Goebel F, Louvet C, Andre T, Carola E, Lotz JP, Molitor JL Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:1338-42. 62. Maindrault-Goebel F, De Gramont A, Gilles V, Lotz JP, Tournigand C, Mabro M et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour-5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Ann Oncol 2000;11;11:1477-83. 63. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. 64. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44 65. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the Epidermal Growth Factor Receptor by immunohistochemistry. J Clin Oncol 2005;23;1803-10 66. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4720-6. 67. Maindrault-Goebel F, Tournigand C, Andre T, Carola E, Mabro M, Artru P, et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol 2004;15:1210-4. 68. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001. 69. Chester JD, Dent JT, Wilson G, Ride E, Seymour MT. Protracted infusional 5-fluorouracil (5FU) with bolus mitomycin C in 5-FU-resistant colorectal cancer. Ann Oncol 2000;11:235-7. 70. Seitz JF, Perrier H, Giovannini M, Bernardini D, Capodano G, Girodengo L, Bardou VJ. 5Fluorouracil, high dose folinic acid and mitomycin-C combination chemotherapy in previously treated patients with advanced colorectal carcinomas. J Chemotherapy 1998;10:258-65. 71. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006;94:798-805. 72. Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, et al. Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006;13:58-65. 73. Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Francaise de Cancerologie Digestive. Br J Surg 1995;82:1397-400. 74. Louafi S, Allonier C, Bouché O, Raoul JL, Mousseau M, Deguiral P, et al. Cancer colorectal métastasé : faut-il retirer le primitif ? (abstract). Gastroenterol Clin Biol 2005;29:A6. 75. Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD. Nonoperative management of primary colorectal cancer in patients with stage IV disease. Ann Surg Oncol 1999;6:651-7. 76. Tebbutt NC, Norman AR, Cunningham D, Hill ME, Tait D, Oates J, et al. Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases. Gut 2003;52:568-73. 77. Pautrat K, Benoist S, Mitry E, Penna C, Rougier P, Nordlinger B. Faut il réséquer la tumeur primitive en cas de cancer colorectal avec métastases hépatiques (MH) synchrones non résécables ? Etude cas-témoins chez 59 malades. Ann Chir 2003;128:657. 78. Michel P, Roque I, Di Fiore F, Langlois S, Scotte M, Teniere P, et al. Colorectal cancer with non-resectable synchronous metastases : should the primary tumor be resected ? Gastroenterol Clin Biol 2004;28:434-7. 79. Conroy T, Adenis A. Standards, options et recommandations pour la surveillance après traitement d'un cancer du côlon. Bull Cancer 1998;85:152­9 80. Falcone A, Masi G, Brunetti I, Benedetti G, Bertetto O, Picone V, et al. The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) (abstract). J Clin Oncol 2006;24(Suppl 18S):3513a. 81. Gruenberger T, Gruenberger B, Scheithauer W. Neoadjuvant therapy with bevacizumab. J Clin Oncol 2006;24:2592-3 ; 82. Michael M, Vancutsem E, Kretzschmar A, Berry S, Rivera F, Dibartolomeo M, et al. Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat-study (abstract). J Clin Oncol 2006;24 (Suppl 18S):3523a. 83. Labianca R, Floriani I, Cortesi E, Isa L, Zaniboni A, Marangolo M, et al. Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial (abstract). J Clin Oncol 2006;24 (Suppl 18S):3505a. 84. Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, Andre T, Bennamoun M, et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study (abstract). J Clin Oncol 2006;24 (Suppl 18S):3504a. 85. Hochster HS, Hart LL, Ramanathan RK, Hainsworth JD, Hedrick EE, Childs BH. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study (abstract). J Clin Oncol 2006;24 (Suppl 18S):3510a. 86. Nordlinger B, Sorbye H, Collette L, Glimelius B, Poston GJ, Schlag PM, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007;25(Suppl 18S):LBA5 87. Elias D, Raynard B, Farkhondeh F, Goéré D, Rouquié D, Ciuchendea R, et al. Peritoneal carcinomatosis of colorectal origin. Long term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol 2006; 30: 1200-4 88. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2007 Sep 28 89. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-403. 90. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005;23:4881-7. 91. Feliu J, Castanon C, Salud A, Mel JR, Escudero P, Pelegrin A, et al. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer 2005;93:1230-5. 92. Hoff PM, Wolff RA, Xiong H, Jones D, Lin E, Eng C,et al. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer 2006;106:2241-6. 93. Giantonio BJ, Catalano PJ, O'Dwyer PJ, Meropol NJ, Benson AB. Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group's Study E3200 (abstract). J Clin Oncol 2006;24(Suppl 18S):3538a. 94. Tabernero J, Cervantes A, Martinelli E, Vega-Villegas E, Rojo F, Pérez-Fidalgo A, et al. Optimal dose of cetuximab (C) given every 2 weeks (q2w): A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (q1w) and q2w schedules in patients (pts) with metastatic colorectal cancer (mCRC) (abstract). J Clin Oncol 2006;24(Suppl 18S):3085a. 95. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer. 2005;93:510-4. 96. Lim do H, Park YS, Park BB, Ji SH, Lee J, Park KW,et al. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol 2005;56:10-4. 97. Fuchs C, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.. J Clin Oncol 2007;25:4779-86. 98. Sugrue M, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Steis R, Dong W, Sarkar S, Grothey A. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol 2006;24(Suppl 18S):3535a. 99. Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 2006;64:1295-8. 100. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370:143-52 101. Bouché O, Castaing M, Etienne PL, Texereau P, Auby D, Bedenne L, et al. Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): Preliminary results. J Clin Oncol 2007;25(Suppl 18S):4069a. 102. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007;370:135-42. 103. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. XELOX compared to FOLFOX4: Survival and response results from XELOX-1/ NO16966, a randomized phase III trial of first-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007;25(Suppl 18S):4030a 104. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007;25(Suppl 18S):4029a. 105. Diaz-Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 2007;25:4224-30 106. Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007;25(Suppl 18S):4028a. 107. Schmiegel WH, Reinacher-Schick A, Freier W, Dietrich G, Arnold D, Kanzler S, et al. Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group. J Clin Oncol 2007;25(Suppl 18S):4034a 108. Van Cutsem E, Nowacki M, Lang I, Cascinu S, Shchepotin I, Maurel J, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 2007;25(Suppl 18S):4000a. 109. Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, Andre A, Bennamoun M, et al. Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 2007;25(Suppl 18S):4013a. 110. Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, et al. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006;17:855-7. 111. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-5. 112. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-9. 113. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7 114. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007;67:2643-8. 115. De Roock W, De Schutter J, De Hertogh G, Janssens M, Biesmans B, Personeni N, et al. KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab. J Clin Oncol 2007;25(Suppl 18S):4132a. 116. Lievre A, Bachet JB , Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations is an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2007 (sous presse) 117. Rothenberg ML, Navarro M, Butts C, Y. Bang Y, Cox JV, Goel R, et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007;25(Suppl 18S):4031a. 118. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64 119. Amado RG, Wolf M, Freeman D, Peeters M, Van Cutsem E, Siena S, et al. Wild-type KRAS is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer: Results From a Randomized, Controlled Trial.Eur J Cancer 2007; 5(Suppl 8):7LB 120. Pfeiffer P, Bjerregaard JK, C. Qvortrup C, Jensen BV, Yilmaz M, Nielsen D. Simplification of cetuximab (Cet) administration: double dose every second week as a 60 minute infusion. J Clin Oncol 2007;25(Suppl 18S):4133a. 121. Siena S, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aranda Aguilar E, et al. Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC): Findings from the MABEL study. J Clin Oncol 2007;25(Suppl 18S):4137a 122. Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007;6:529-31 123. Reidy DL, Chung KY, Timoney JP, Park VJ, Hollywood E, Sklarin NT, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007 ;25:2691-5.